Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease

Antileukotriene therapy by reducing tau phosphorylation improves synaptic integrity and cognition of P301S transgenic mice

(2018) Phillip F. Giannopoulos et al.   AGING CELL

DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivatives

(2018) Fernanda Neumann et al.   Scientific Reports

Phosphorylation of different tau sites during progression of Alzheimer’s disease

(2018) Joerg Neddens et al.   Acta Neuropathologica Communications

Expression of Alzheimer-Like Pathological Human Tau Induces a Behavioral Motor and Olfactory Learning Deficit in Drosophila melanogaster

(2018) Cindy Beharry et al.   JOURNAL OF ALZHEIMERS DISEASE

Protein Phosphorylation is a Key Mechanism in Alzheimer’s Disease

(2017) Joana Oliveira et al.   JOURNAL OF ALZHEIMERS DISEASE

An acetylation–phosphorylation switch that regulates tau aggregation propensity and function

(2017) Yari Carlomagno et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Amyloid-β and tau complexity — towards improved biomarkers and targeted therapies

(2017) Juan Carlos Polanco et al.   Nature Reviews Neurology

Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes

(2017) Susana García-Cerro et al.   NEUROBIOLOGY OF DISEASE

Therapeutic strategies for the treatment of tauopathies: Hopes and challenges

(2016) Mansi R. Khanna et al.   Alzheimers & Dementia

Tau: From research to clinical development

(2016) David M. Holtzman et al.   Alzheimers & Dementia

Tau physiology and pathomechanisms in frontotemporal lobar degeneration

(2016) Liviu-Gabriel Bodea et al.   JOURNAL OF NEUROCHEMISTRY

Abnormal tau induces cognitive impairment through two different mechanisms: synaptic dysfunction and neuronal loss

(2016) J. Di et al.   Scientific Reports

Synthesis, Stereochemical Analysis, and Derivatization of Myricanol Provide New Probes That Promote Autophagic Tau Clearance

(2015) Mackenzie D. Martin et al.   ACS Chemical Biology

DYRK1A overexpression enhances STAT activity and astrogliogenesis in a Down syndrome mouse model

(2015) N. Kurabayashi et al.   EMBO REPORTS

Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25–35 peptide administration in mice

(2015) Gaëlle Naert et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

A novel DYRK1A (Dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologiesin vitro

(2015) Séverine Coutadeur et al.   JOURNAL OF NEUROCHEMISTRY

FDA-approved small-molecule kinase inhibitors

(2015) Peng Wu et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

The kinase DYRK1A reciprocally regulates the differentiation of Th17 and regulatory T cells

(2015) Bernard Khor et al.   eLife

DYRK1A: A Potential Drug Target for Multiple Down Syndrome Neuropathologies

(2014) Walter Becker et al.   CNS & Neurological Disorders-Drug Targets

Phosphorylation and Inactivation of Glycogen Synthase Kinase 3β (GSK3β) by Dual-specificity Tyrosine Phosphorylation-regulated Kinase 1A (Dyrk1A)

(2014) Woo-Joo Song et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Mechanism of dual specificity kinase activity of DYRK1A

(2013) Agnes Walte et al.   FEBS Journal

Tau pathology and neurodegeneration

(2013) Maria Grazia Spillantini et al.   LANCET NEUROLOGY

Alzheimer disease therapy—moving from amyloid-β to tau

(2013) Ezio Giacobini et al.   Nature Reviews Neurology

Tau protein kinases: Involvement in Alzheimer's disease

(2012) Ludovic Martin et al.   AGEING RESEARCH REVIEWS

Hypothermia-induced hyperphosphorylation: A new model to study tau kinase inhibitors

(2012) Alexis Bretteville et al.   Alzheimers & Dementia

A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer’s disease

(2011) Tomohiro Onishi et al.   JOURNAL OF NEUROCHEMISTRY

The Many Faces of Tau

(2011) Meaghan Morris et al.   NEURON

Dyrk1A Positively Stimulates ASK1-JNK Signaling Pathway during Apoptotic Cell Death

(2011) Hyoung Kyoung Choi et al.   Experimental Neurobiology

High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation

(2010) David O Azorsa et al.   BMC GENOMICS

The role of DYRK1A in neurodegenerative diseases

(2010) Jerzy Wegiel et al.   FEBS Journal

Developmental regulation of tau phosphorylation, tau kinases, and tau phosphatases

(2009) Yang Yu et al.   JOURNAL OF NEUROCHEMISTRY

The JNK pathway amplifies and drives subcellular changes in tau phosphorylation

(2009) J. Vogel et al.   NEUROPHARMACOLOGY

Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome

(2008) Fei Liu et al.   FASEB JOURNAL

Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer’s disease

(2007) Soo-Ryoon Ryoo et al.   JOURNAL OF NEUROCHEMISTRY